Monoclonal gammopathy of undetermined significance historical perspective: Difference between revisions
No edit summary |
Iqra Qamar (talk | contribs) No edit summary |
||
| (One intermediate revision by one other user not shown) | |||
| Line 2: | Line 2: | ||
{{Monoclonal gammopathy of undetermined significance }} | {{Monoclonal gammopathy of undetermined significance }} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{OK}} | ||
==Overview== | ==Overview== | ||
[[Monoclonal gammopathy of undetermined significance]] was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. Introduced more than 35 years ago, the term monoclonal gammopathy of undetermined signficance was used because of the increased risk of patients for the development of symptomatic MM, WM, Light-chain (AL) [[amyloidosis]], or a related disorder during long-term follow-up. | |||
==Historical Perspective== | ==Historical Perspective== | ||
===Discovery=== | ===Discovery=== | ||
[[Monoclonal gammopathy of undetermined significance]] was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. <ref name="pmid14004528">{{cite journal |vauthors=WALDENSTROM J |title=Studies on conditions associated with disturbed gamma globulin formation (gammopathies) |journal=Harvey Lect. |volume=56 |issue= |pages=211–31 |date=1960 |pmid=14004528 |doi= |url=}}</ref> Introduced more than 35 years ago, the term monoclonal gammopathy of undetermined signficance was used because of the increased risk of patients for the development of symptomatic MM, WM, light-chain (AL) [[amyloidosis]], or a related disorder during long-term follow-up.<ref name="pmid15244381">{{cite journal |vauthors=Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ |title=Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later |journal=Mayo Clin. Proc. |volume=79 |issue=7 |pages=859–66 |date=July 2004 |pmid=15244381 |doi=10.1016/S0025-6196(11)62151-4 |url=}}</ref><ref name="pmid645746">{{cite journal |vauthors=Kyle RA |title=Monoclonal gammopathy of undetermined significance. Natural history in 241 cases |journal=Am. J. Med. |volume=64 |issue=5 |pages=814–26 |date=May 1978 |pmid=645746 |doi= |url=}}</ref> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Latest revision as of 11:23, 24 October 2018
|
Monoclonal gammopathy of undetermined significance Microchapters |
|
Differentiating Monoclonal gammopathy of undetermined significance from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Monoclonal gammopathy of undetermined significance historical perspective On the Web |
|
American Roentgen Ray Society Images of Monoclonal gammopathy of undetermined significance historical perspective |
|
FDA on Monoclonal gammopathy of undetermined significance historical perspective |
|
on Monoclonal gammopathy of undetermined significance historical perspective |
|
Monoclonal gammopathy of undetermined significance historical perspective in the news |
|
Blogs on Monoclonal gammopathy of undetermined significance historical perspective |
|
Directions to Hospitals Treating Monoclonal gammopathy of undetermined significance |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omer Kamal, M.D.[2]
Overview
Monoclonal gammopathy of undetermined significance was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. Introduced more than 35 years ago, the term monoclonal gammopathy of undetermined signficance was used because of the increased risk of patients for the development of symptomatic MM, WM, Light-chain (AL) amyloidosis, or a related disorder during long-term follow-up.
Historical Perspective
Discovery
Monoclonal gammopathy of undetermined significance was first discivered by Jan G. Waldenstrom in 1960 “essential hyperglobulinemia” or “benign monoclonal gammopathy” and then as monoclonal gammopathy of undetermined significance by Robert A. Kyle in 1978. [1] Introduced more than 35 years ago, the term monoclonal gammopathy of undetermined signficance was used because of the increased risk of patients for the development of symptomatic MM, WM, light-chain (AL) amyloidosis, or a related disorder during long-term follow-up.[2][3]
References
- ↑ WALDENSTROM J (1960). "Studies on conditions associated with disturbed gamma globulin formation (gammopathies)". Harvey Lect. 56: 211–31. PMID 14004528.
- ↑ Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ (July 2004). "Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later". Mayo Clin. Proc. 79 (7): 859–66. doi:10.1016/S0025-6196(11)62151-4. PMID 15244381.
- ↑ Kyle RA (May 1978). "Monoclonal gammopathy of undetermined significance. Natural history in 241 cases". Am. J. Med. 64 (5): 814–26. PMID 645746.